Last updated on October 2017

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance Safety Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis


Brief description of study

This study will assess the effect of inhaled AZD5634 on Mucociliary clearance (MCC) in patients with Cystic fibrosis (CF) after single-dose administration.

Detailed Study Description

The primary pharmacodynamic endpoint will be the average whole lung particle clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles (colloids) at Visits 2 and 3 (%MCC 0-60, whole).

Clinical Study Identifier: NCT02950805

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

AstraZeneca Clinical Study Information Center

Research Site
Birmingham, AL United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Baltimore, MD United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Chapel Hill, NC United States
  Connect »